Preview

Онкологическая колопроктология

Расширенный поиск

ПЕРСПЕКТИВЫ ЛЕЧЕНИЯ БОЛЬНЫХ РАКОМ ТОЛСТОЙ КИШКИ С МУТАЦИЕЙ В ГЕНЕ BRAF

https://doi.org/10.17650/2220-3478-2014-0-3-9-16

Полный текст:

Аннотация

Рак толстой кишки (РТК) представляет собой гетерогенную группу опухолей, отличающихся как механизмами канцерогенеза и, следовательно, молекулярными изменениями, так и прогнозом течения болезни и особенностями терапии. К настоящему времени в клинической практике уже необходимо оценивать статус генов KRAS и NRAS для определения возможности назначения анти-EGFR препаратов при метастатическом РТК. Обособленной группой больных с неблагоприятным течением болезни являются пациенты с мутацией в гене BRAF в опухоли. В данном обзоре мы сконцентрируемся на биологических особенностях РТК с мутацией в гене BRAF, эпидемиологии, клинических характеристиках болезни на разных стадиях, выборе терапии и перспективных направлениях лечения данной группы пациентов.

Об авторах

М. Ю. Федянин
ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» РАМН, Москва
Россия


А. А. Трякин
ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» РАМН, Москва
Россия


С. А. Тюляндин
ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» РАМН, Москва
Россия


Список литературы

1. Mendelsohn J., Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21(14):2787–99.

2. Mayer A., Takimoto M., Fritz E. et al. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 1993;71(8):2454–60.

3. Custodio A., Feliu J. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: Beyond KRAS mutations. Crit Rev Oncol Hematol 2013;85(1):45–81.

4. Di Fiore F., Blanchard F., Charbonnier F. et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 2007;96:1166–9.

5. Lievre A., Bachet J.B., Boige V. et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374–9.

6. Niault T.S., Baccarini M. Targets of Raf in tumorigenesis. Carcinogenesis 2010;31(7):1165–74.

7. Guan K.L., Figueroa C., Brtva T.R. et al. Negative regulation of the serin/threonine kinase B-RAF by Akt. J Biol Chem 2000;275(35):27354–9.

8. Roskoski R. Jr. RAF protein-serine/threonine kinases: structure and regulation. Biochem Biophys Res Commun 2010;399(3):313–7.

9. Pakneshan S., Salajegheh A., Smith R.A., Lam A.K. Clinicopathological relevance of BRAF mutations in human cancer. Pathology 2013;45:346–56.

10. Jones D.T., Kocialkowski S., Liu L. et al. Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion inactivating the MAPK pathway in pilocytic astrocytoma. Oncogene 2009;28(20):2119–23.

11. Lawson A.R., Tatevossian R.G., Phipps K.P. et al. RAF gene fusions are specific to pilocytic astrocytoma in a broad paediatric brain tumour cohort. Acta Neuropathol 2010;120(2):271–3.

12. Ogino S., Nosho K., Kirkner G.J. et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009;58(1):90–6.

13. Samowitz W.S., Sweeney C., Herrick J. et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005;65(14):6063–70.

14. Barault L., Veyrie N., Jooste V. et al. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer 2008;122(10):2255–9.

15. Bosman F.T., Carneiro F., Hruban R.H., Theise N.D. WHO: Classification of tumours of the digestive system, 4th ed. Lyon: IARC Press, 2010.

16. Wang L., Cunningham J.M., Winters J.L. et al. BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res 2003;63:5209–12.

17. Roth A., Tejpar S., Delorenzi M. et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2009;28:466–74.

18. Roth A., Klingbiel D., Yan P. et al. Molecular and clinical determinants of survival following relapse after curative treatment of stage II–III colon cancer (CC): results of the translational study of PETACC 3-EORTC 40993-SAKK 60-00 trial. J Clin Oncol 2010;28(suppl; abstr 3504).

19. Dienstmann R., Guinney J., Delorenzi M. et al. Colorectal Cancer Subtyping Consortium (CRCSC) identification of a consensus of molecular subtypes. J Clin Oncol 2014;32:5s (suppl; abstr 3511).

20. Artale S., Sartore-Bianchi A., Veronese S.M. et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 2008; 26(25):4217–9.

21. Kopetz S., Overman M.J., Chen K. et al. Mutation and copy number discordance in primary versus metastatic colorectal cancer (mCRC). J Clin Oncol 2014;32:5s (suppl; abstr 3509).

22. Graham D.M., Arseneault M., Sukhai M.A. et al. Analysis of clonal evolution in colorectal cancer. J Clin Oncol 2014;32:5s (suppl; abstr 3510).

23. Zlobec I., Bihl M.P., Schwarb H. et al. Clinicopathological and protein characterization of BRAF- and K-RASmutated colorectal cancer and implications for prognosis. Int J Cancer 2010;127(2): 367–80.

24. Tie J., Gibbs P., Lipton L. et al. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAFV600E mutation. Int J Cancer 2011;128:2075–84.

25. Pinheiro M., Ahlquist T., Danielsen S.A. et al. Colorectal carcinomas with microsatellite instability display a different pattern of target gene mutations according to large bowel site of origin. BMC Cancer 2010;10:587.

26. Bokemeyer C., Kohne C., Rougier P. et al. Cetuximab with chemotherapy (CT) as firstline treatment for metastatic colorectal cancer (mCRC): analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status. J Clin Oncol 2010;28(Suppl.) [abstract 3506].

27. Hutchins G., Southward K., Handley K. et al. Value of mismatch repair, KRAS and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 2011;29:1261–70.

28. Safaee Ardekani G., Jafarnejad S.M., Tan L., et al. The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS One 2012;7(10):e47054.

29. Popat S., Hubner R., Houlston R.S. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005;23:609–18.

30. Gavin P.G., Colangelo L.H., Fumagalli D. et al. Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res 2012;18(23):6531–41.

31. Koopman M., Kortman G.A., Mekenkamp L. et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer 2009;100:266–73.

32. Yuan Z.X., Wang X.Y., Qin Q.Y. et al. The prognostic role of BRAF mutation in metastatic colorectal cancer receiving anti-EGFR monoclonal antibodies: a metaanalysis. PLoS One 2013;8(6):e65995. doi:10.1371/journal.pone.0065995.

33. Mao C., Liao R.Y., Qiu L.X. et al. BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis. Mol Biol Rep 2011;38(4):2219–23.

34. Xu Q., Xu A.T., Zhu M.M. et al. Predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a metaanalysis. J Dig Dis 2013;14(8):409–16.

35. Bokemeyer C., Van Cutsem E., Rougier P. et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomized clinical trials. Eur J Cancer 2012;48:1466–75.

36. Van Cutsem E., Kohne C.H., Lang L. et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011;29:2011–9. doi:10.1200/JCO.2010.33.5091.

37. Seymour M.T., Brown S.R., Richman S. et al. Addition of panitumumab to irinotecan: results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC). J Clin Oncol 2011;29 (Suppl.) [abstract 3523].

38. Tol J., Dijkstra J.R., Klomp M. et al. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur J Cancer 2010;46:1997–2009.

39. Di Nicolantonio F., Martini M., Molinari F. et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008;26(35):5705–12.

40. De Roock W., Claes B., Bernasconi D. et al. Effects of KRAS, BRAF, NRAS and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010;11(8):753–62.

41. Richman S.D., Seymour M.T., Chambers P. et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009;27:5931–7.

42. Hutchins G., Southward K., Handley K. et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 2011;29:1261–70.

43. Ogino S., Shima K., Meyerhardt J.A. et al. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res 2012;18:890–900.

44. Ince W.L., Jubb A.M., Holden S.N. et al. Association of k-ras, b-raf and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 2005;97(13):981–9.

45. Loupakis F., Cremolini C., Salvatore L. et al. FOLFOXIRI plus bevacizumab as firstline treatment in BRAF mutant metastatic colorectal cancer. Eur J Cancer 2014 Jan;50(1):57–63.

46. Loupakis F., Cremolini C., Lonardi S. et al. Subgroup analyses in RAS mutant, BRAF mutant and all-wt mCRC pts treated with FOLFOXIRI plus bevacizumab (bev) or FOLFIRI plus bev in the TRIBE study. J Clin Oncol 2014;32:5s (suppl; abstr 3519).

47. Kopetz S., Desai J., Chan E. et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J Clin Oncol 2010;28(15 suppl). Abstr. 3534. 48. Liu L., Shi H., Bleam M.R. et al. Antitumor effects of dabrafenib, trametinib, and panitumumab as single agents and in combination in BRAF-mutant colorectal carcinoma (CRC) models. J Clin Oncol 2014;32:5s (suppl; abstr 3513).

48. Geel R.V., Elez E., Bendell J.C. et al. Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor BYL719 in patients with advanced BRAF-mutant colorectal cancer. J Clin Oncol 2014;32:5s (suppl; abstr 3514).

49. Bendell J.C., Atreya C.E., Andrй T. et al. Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC). J Clin Oncol 2014;32:5s (suppl; abstr 3515).

50. Hong D.S., Morris V.K., Fu S. et al. Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated advanced cancers and metastatic colorectal cancer. J Clin Oncol 2014;32:5s (suppl; abstr 3516).

51. Tabernero J., Chan E., Baselga J. et al. VE-BASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): Activity of vemurafenib (VEM) with or without cetuximab (CTX) in colorectal cancer (CRC). J Clin Oncol 2014;32:5s (suppl; abstr 3518).

52. Corcoran R.B., Atreya C.E., Falchook G.S. et al. Phase 1-2 trial of the BRAF inhibitor dabrafenib (D) plus MEK inhibitor trametinib (T) in BRAF V600 mutant colorectal cancer (CRC): Updated efficacy and biomarker analysis. J Clin Oncol 2014;32:5s (suppl; abstr 3517).


Для цитирования:


Федянин М.Ю., Трякин А.А., Тюляндин С.А. ПЕРСПЕКТИВЫ ЛЕЧЕНИЯ БОЛЬНЫХ РАКОМ ТОЛСТОЙ КИШКИ С МУТАЦИЕЙ В ГЕНЕ BRAF. Онкологическая колопроктология. 2014;(3):9-16. https://doi.org/10.17650/2220-3478-2014-0-3-9-16

For citation:


Fedyanin M.Y., Tryakin A.A., Tjulandin S.A. PROMISES FOR TREATING COLON CANCER PATIENTS WITH BRAF GENE MUTATION. Colorectal Oncology. 2014;(3):9-16. (In Russ.) https://doi.org/10.17650/2220-3478-2014-0-3-9-16

Просмотров: 506


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2413-0583 (Online)